Privia Health Group, Inc. (PRVA) stock price, news, quote and history
This article provides a detailed overview of Privia Health Group, Inc. (PRVA), including its current stock price, financial statistics, and recent performance. It covers key financial metrics like market cap, P/E ratio, and EPS, alongside a company overview describing its operations as a physician-enablement company. The content also features analyst insights, earnings trends, and performance comparisons against the S&P 500 benchmark.
Privia Health stock reports strong Q2 growth and guidance
Privia Health (PRVA) reported strong Q2 2026 results, with revenue up 21.40% year over year to USD 632.63 million, significantly beating analyst expectations. The company also provided fiscal 2026 guidance targeting the high end of USD 2.35 billion to USD 2.45 billion. Analysts largely rate the stock as a "buy," with a consensus 12-month price target of USD 31.00.
Privia Health Group, Inc. (PRVA) Stock forecasts
Argus has lowered its target price for Privia Health Group, Inc. (PRVA) to $18.00. The current stock price for PRVA is $19.71. Privia Health Group Inc. is described as a technology-driven, national physician-enablement company.
Privia Health Group stock hits 52-week low at 19.52 USD
Privia Health Group Inc.'s stock has fallen to a 52-week low of $19.52, reflecting a 14.45% decline over the past year and a -16.28% year-to-date return amidst challenges in the healthcare sector. Despite this, InvestingPro analysis suggests the stock is undervalued and in oversold territory, with analysts maintaining a bullish outlook and price targets between $24 and $40. The downturn comes even after the company reported strong Q2 2026 financial results, surpassing Wall Street expectations for both earnings and revenue.
Privia Health Group (PRVA) Stock Looks Rich Against Current Earnings
Privia Health Group (PRVA) stock closed at US$19.85, but its P/E ratio of 90.2x is significantly higher than the healthcare sector average of 24.0x, suggesting it is overvalued based on current earnings. Despite a 23.1% fall in share price over the past five years, the market is paying a rich premium for its current profits. Simply Wall St's analysis indicates that the stock is overvalued when compared to a tailored benchmark considering its growth profile, margins, size, and risk.
Privia Health Group Inc. (PRVA) Shareholding Pattern – Promoters, FIIs & DIIs
This article provides a detailed shareholding pattern for Privia Health Group Inc. (PRVA), listing institutional investors with holdings over 1% and their changes in shares. It also includes recent insider trading activities, specifically sell transactions by David Mountcastle and Parth Mehrotra in March 2026. Financial metrics for PRVA, such as market cap, revenue, P/E ratio, and dividend yield, are also presented as of September 16, 2026.
Responsive Playbooks and the PRVA Inflection
Privia Health Group Inc. (NASDAQ: PRVA) is showing weak near and mid-term sentiment but a neutral long-term outlook, with its support levels currently being tested. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles and offering specific entry, target, and stop-loss zones. Despite the weak sentiment, an exceptional 41.8:1 risk-reward setup is identified, targeting a 12.4% gain against a 0.3% risk.
New investor group tops 5% stake in Privia Health (NASDAQ: PRVA)
An investment group including Puma Growth Holdings and Rubicon Founders has disclosed a 5.07% beneficial ownership stake in Privia Health Group, Inc. (PRVA), acquired for approximately $138.4 million. The group intends to review its investment continuously and may engage with company management and other stakeholders, signaling an active-investor approach. This disclosure was made via a Schedule 13D filing, indicating potential intent to influence company control.
Adam Boehler Discloses Investment in Privia Health Group with 5.07% Stake
Adam Boehler, through Rubicon Founders, has acquired a 5.07% stake in Privia Health Group, Inc. common stock, as disclosed in a Schedule 13D filing on September 8, 2026. Boehler intends to engage with Privia Health's leadership and other stakeholders to review his investment, with the possibility of buying or selling shares based on ongoing evaluations. Boehler is a prominent American investor known for founding Rubicon Founders, a healthcare-focused investment firm.
Healthcare Technology for Providers Stocks Q2 Teardown: Privia Health (NASDAQ:PRVA) Vs The Rest
This article provides a Q2 earnings teardown for healthcare technology providers, focusing on Privia Health (NASDAQ:PRVA) and its peers. It highlights the strong Q2 performance of the sector, with revenues beating estimates, and details the individual results of Privia Health, Evolent Health (NYSE:EVH), Astrana Health (NASDAQ:ASTH), and Omnicell (NASDAQ:OMCL), noting their revenue growth, analyst estimate beats, and stock performance. The article also touches on market risks and the impact of AI and geopolitics.
(PRVA) Volatility Zones as Tactical Triggers
This article analyzes Privia Health Group Inc. (NASDAQ: PRVA), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies key support and resistance levels, presenting an exceptional risk-reward setup. The piece also outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
Enterprise value to revenue forward of Privia Health Group, Inc. – NASDAQ:PRVA
The article focuses on the enterprise value to revenue forward metric for Privia Health Group, Inc. (NASDAQ: PRVA). It appears to be a financial data point presented by TradingView, indicating a specific valuation multiple for the company. The content primarily lists navigation and administrative information, with the core financial data point being "Enterprise value to revenue forward."
Price to sales forward of Privia Health Group, Inc. – NASDAQ:PRVA
The article displays the "Price to sales forward" metric for Privia Health Group, Inc. (NASDAQ: PRVA) on a TradingView page. It shows a table with "Period," "Value," "Change," and "Change %" but the specific financial data is not populated. The content primarily consists of navigation links and general information about TradingView.
Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?
Privia Health Group (PRVA) recently reported strong Q2 2026 results, raising its full-year revenue outlook and appointing an experienced healthcare executive, Dr. Opella Ernest, to its Board. This positive guidance and new expertise could significantly influence the company's long-term investment narrative, especially in scaling its value-based care model. Investors should consider these developments while also weighing potential risks like rising healthcare labor and technology costs.
Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?
Privia Health Group (PRVA) recently reported strong Q2 2026 results with increased sales and profitability, raising its full-year 2026 GAAP revenue outlook to the high end of its prior range. The company also appointed Dr. Opella Ernest to its Board, bringing valuable healthcare expertise. Investors should consider how this stronger guidance and new board addition impact Privia's investment narrative, particularly concerning its ability to manage rising costs and scale its value-based care model.
Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
Privia Health Group, Inc. has announced the appointment of Dr. Opella Ernest to its Board of Directors, effective September 1, 2026. Dr. Ernest, who also joins the Compliance Committee, brings over 20 years of healthcare executive experience, including significant expertise in value-based care and clinical operations. This appointment is expected to bolster Privia Health's growth and network expansion across the U.S.
Privia Health adds Dr. Opella Ernest to board of directors
Privia Health Group Inc. (NASDAQ:PRVA) has announced the appointment of Dr. Opella Ernest to its board of directors, effective September 1, 2026. Dr. Ernest, who currently serves as President of HCSC Markets at Health Care Service Corporation, will also join the board’s Compliance Committee. Her extensive background in healthcare leadership and clinical practice is expected to bolster Privia Health's strategic direction.
Form 8K Privia Health Group Inc For: 18 August By Investing.com
This article announces that Privia Health Group Inc. filed a Form 8K on August 18. The Form 8K is a crucial document used by public companies to notify investors of unscheduled material events or corporate changes. The article itself is a brief notification from Investing.com, providing no further details about the content of the filing beyond its date and the company involved.
Privia Health adds Dr. Opella Ernest to board of directors By Investing.com
Privia Health Group, Inc. has announced the appointment of Dr. Opella Ernest to its board of directors, effective September 1, 2026. Dr. Ernest, currently President of HCSC Markets at Health Care Service Corporation, will also serve on the board’s Compliance Committee. She brings extensive experience from various leadership roles in the healthcare industry and currently serves on other prominent boards.
Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors
Privia Health Group, Inc. has announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026. Dr. Ernest, who brings over 20 years of healthcare executive experience and significant value-based care and clinical expertise, will also join the Compliance Committee. Her experience as President, HCSC Markets at Health Care Service Corporation and her background as a board-certified family physician are expected to be beneficial for Privia Health's continued growth.
Form 8K Privia Health Group Inc For: 18 August By Investing.com
This article announces the filing of a Form 8K by Privia Health Group Inc. on August 18. The brief update, published by Investing.com, indicates a regulatory filing event for the company.
A 20-year healthcare executive is set to join Privia Health's board
Privia Health (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D., a healthcare executive with over 20 years of experience, to its Board of Directors, effective September 1, 2026. Dr. Ernest, currently President of HCSC Markets at Health Care Service Corporation, will also join the Board’s Compliance Committee, bringing significant clinical and value-based care expertise to the company. This strategic addition aims to support Privia Health's growth and expansion of provider networks across the United States.
Bank of America Corp DE Cuts Holdings in Privia Health Group, Inc. $PRVA
Bank of America Corp DE reduced its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 11.1% in the first quarter, selling 157,580 shares and holding 1,256,178 shares valued at $25.84 million. Despite this, other institutional investors have either increased their holdings or acquired new positions. Analysts currently rate Privia Health Group with a "Moderate Buy" consensus, and the company recently surpassed earnings estimates in its quarterly report.
OneDigital Investment Advisors LLC Purchases New Stake in Privia Health Group, Inc. $PRVA
OneDigital Investment Advisors LLC has acquired a new stake in Privia Health Group, Inc. (NASDAQ:PRVA), purchasing 258,561 shares valued at approximately $6.65 million. This transaction gives OneDigital Investment Advisors a 0.21% stake in the company, where institutional investors collectively own 94.48%. Despite a generally positive "Moderate Buy" rating from analysts with an average price target of $31.00, company insiders have recently sold a significant number of shares totaling $8.63 million.
GSA Capital Partners LLP Invests $1.67 Million in Privia Health Group, Inc. $PRVA
GSA Capital Partners LLP has invested $1.67 million in Privia Health Group, Inc. by acquiring 65,048 shares during the second quarter. While institutional investors own a significant portion of the company, insiders have been net sellers, divesting shares worth approximately $8.63 million in the last 90 days. Despite insider selling, analysts maintain a "Moderate Buy" rating for Privia Health, with an average price target of $31.00.
ETFs Investing in Privia Health Group, Inc. Stocks
This article lists various ETFs that invest in Privia Health Group, Inc. (PRVA) stocks, providing detailed financial information for each fund. The data includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The ETFs primarily target small-cap and health care sectors, offering investors diversified opportunities with potentially lower risk.
PRVA|Privia Health Group Inc|Price:22.000|Chg%:+0.240
This article provides a detailed overview of Privia Health Group Inc (PRVA) stock, including its current price, market data, key figures, and financial performance metrics. It also features a "TradingKey Stock Score," analyst ratings with a target price, and a company profile outlining its business model and shareholder information. The stock currently has an overall "Buy" rating from analysts with a significant upside potential.
Oppenheimer Asset Management Inc. Purchases New Stake in Privia Health Group, Inc. $PRVA
Oppenheimer Asset Management Inc. recently acquired 226,999 shares of Privia Health Group, Inc. (NASDAQ:PRVA) for approximately $5.84 million, increasing institutional ownership to 94.48%. Despite some insider selling, analysts maintain a "Moderate Buy" consensus with an average price target of $31.00. The stock opened at $22.00, below its 50-day moving average, with a market capitalization of $2.81 billion.
Privia Health (PRVA) Q2 2026 Earnings Call Transcript
Privia Health (PRVA) reported strong Q2 2026 results, with net income up 236.7% and total revenue increasing 21.4% year-over-year. The company expanded into New Jersey, now operating in 25 states, and highlighted the successful integration of recent acquisitions and the deployment of AI applications to enhance efficiency and drive long-term margin expansion. Management raised its full-year 2026 guidance across key financial metrics, expressing confidence in its primary care-centric model and ability to capitalize on value-based care programs despite potential delays in CMS shared savings settlements.
The Top 5 Analyst Questions From Privia Health’s Q2 Earnings Call
Privia Health's Q2 results showed strong revenue growth but missed non-GAAP profit expectations, leading to a negative market reaction. Management attributed revenue growth to robust provider signings and expanded value-based attributed lives. This article highlights the top five analyst questions from the earnings call, covering topics like CMS shared savings payments, EBITDA margin confidence, practice collections growth, AI use cases, and acquisition integration.
Privia Health Group (PRVA) Is Down 5.2% After Q2 Beat And Higher 2026 Outlook - What's Changed
Privia Health Group (PRVA) reported strong Q2 2026 results with increased sales and net income, alongside a raised full-year 2026 revenue outlook to the high end of its previous guidance. Despite this positive financial performance, the stock fell 5.2%. The company's investment narrative centers on its physician enablement model converting patient volumes into revenue, though thin margins and rising labor costs remain key risks.
Privia Health Group (PRVA) Is Down 5.2% After Q2 Beat And Higher 2026 Outlook - What's Changed
Privia Health Group (PRVA) reported strong Q2 2026 results with US$632.63 million in sales and US$9.05 million in net income, and raised its full-year 2026 GAAP revenue guidance to the high end of US$2.35 billion to US$2.45 billion. Despite this positive earnings beat and increased outlook, the stock declined by 5.2%. The article discusses how this performance impacts the company's investment narrative, emphasizing that while top-line growth is strong, potential challenges from rising healthcare labor costs and competition could still constrain profitability, leading to varied fair value estimates among analysts.
Privia Health Group (PRVA) Is Down 5.2% After Raising 2026 Revenue Guidance And Expanding Footprint
Privia Health Group (PRVA) reported strong Q2 2026 results with increased sales and net income, leading management to raise its 2026 GAAP revenue expectations to the top end of its prior guidance range of US$2.35–US$2.45 billion. Despite this positive news and continued expansion into 25 states, the stock price fell by 5.2%. The company's investment narrative focuses on its physician-enablement model, value-based care, and network expansion, but faces near-term risks from rising healthcare labor costs and payer consolidation.
Privia Health Group (PRVA) Stock Faces Cash Flow Questions After Guidance Lift
Privia Health Group's stock saw a modest rise after its Q2 earnings report, which highlighted a 21.4% revenue increase to US$632.6m and adjusted EBITDA growth of 29% to US$37.4m, leading management to lift full-year guidance. While bulls see this as evidence of scale and technology improving unit economics, bears remain concerned about thin free cash flow, low returns on invested capital, and execution risks in its multi-year build-outs and dependence on timely Medicare settlements. The article suggests investors examine whether the improved margins will translate into durable, self-funded free cash flow, especially given recent insider selling.
Earnings To Watch: Privia Health Group Inc (PRVA) Q2 2026 -- GF Value Sees 28% Upside
Privia Health Group Inc (NASDAQ:PRVA) is scheduled to release its Q2 2026 earnings on August 6, 2026, with revenue estimates at $599.19 million and earnings at $0.07 per share. Analyst price targets suggest an average upside of 33.58% from the current price, while GuruFocus estimates a 28.26% upside. Despite a revenue beat in the previous quarter, earnings per share missed analyst expectations.
Privia Health Group, Inc. (PRVA) Stock Price, News, Quote & History
This article provides a detailed financial overview of Privia Health Group, Inc. (PRVA), including its stock price, historical data, key financial metrics, and analyst ratings. As of August 7, 2026, PRVA's stock closed at $22.45, up 2.05%, with a market capitalization of $2.868 billion and a P/E ratio of 102.05. The company operates as a national physician-enablement service, collaborating with healthcare entities to improve workflows and patient care.
Enterprise value to EBITDA forward of Privia Health Group, Inc. – NASDAQ:PRVA
This article provides financial information for Privia Health Group, Inc. (NASDAQ: PRVA), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a financial data snapshot from TradingView, indicating the value and change over a period without further analytical depth.
Privia Health Group, Inc. (NASDAQ:PRVA) Given Average Rating of "Moderate Buy" by Brokerages
Privia Health Group, Inc. (NASDAQ:PRVA) has received an average "Moderate Buy" rating from brokerages, with eleven out of fourteen analysts recommending a buy. The average 12-month price target is $31.15, significantly higher than its current trading price of $23.96. Despite significant insider selling totaling $11.4 million in the last quarter, institutional ownership remains high at 94.48%.
Privia Health Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PRVA)
This article provides details about Privia Health Group, Inc.'s Q2 2026 earnings call presentation. The company reported an EPS of $0.19, missing estimates by $0.05, but revenue reached $632.63M, beating expectations by $31.87M, representing a 21.39% year-over-year increase. The content directs readers to the slide deck published by Privia Health Group, Inc. in conjunction with their earnings call.
Enterprise value to EBIT forward of Privia Health Group, Inc. – NASDAQ:PRVA
The article focuses on the enterprise value to EBIT forward for Privia Health Group, Inc. (NASDAQ: PRVA). It presents financial data and market information related to the company, including its stock market listing on Nasdaq. The content seems to be a snapshot from a financial data platform like TradingView.
Privia Health Group, Inc. 2026: Revenue $632.63M, EPS $0.07— 10-Q Summary
Privia Health Group, Inc. (PRVA) reported strong results for 2026, with revenue reaching $632.63 million and diluted EPS of $0.07. This growth was fueled by an expanding provider network and increased visit volumes. The company also saw significant shifts towards value-based care, with attributed lives increasing by 19% year-over-year.
Privia Health raises 2026 guidance to up to 1.65M attributed lives
Privia Health (PRVA) reported strong Q2 2026 results with revenue up 21.4% to $632.6 million and net income soaring 236.7% to $9.0 million. The company raised its full-year 2026 guidance for GAAP revenue to the high end of $2.35–$2.45 billion and Adjusted EBITDA to $145–$155 million, also increasing its target for value-based attributed lives to 1.625 million–1.65 million. Despite positive financial performance, the stock experienced an 8.18% decline in the session following the announcement.
Privia Health Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PRVA)
Privia Health Group, Inc. (PRVA) published its Q2 2026 earnings call presentation. The company reported an EPS of $0.19, missing estimates by $0.05, but revenue reached $632.63M, beating expectations by $31.87M and representing a 21.39% year-over-year increase. This presentation was released in conjunction with their earnings call.
Privia Health Group, Inc. Stock 12‑Month Price Target Cut to $31.78, Implies 33% Upside
Privia Health Group, Inc.'s stock average price target has been adjusted to $31.78 from $32.11 by 18 analysts, with a range of $24 to $40 per share. This new target suggests a 33% potential upside based on the Aug. 5 closing price. The consensus rating for the company remains "Buy" among 19 analysts.
Privia Health Group Inc (PRVA) Stock Down 8.2% -- Now Undervalued? GF Score: 88/100
Privia Health Group Inc (PRVA) shares fell 8.2% to $22.00, but are considered undervalued by the GF Value™ estimate of $27.63, creating a 20.4% margin of safety. The company has a strong GF Score™ of 88/100, with high ratings for growth and valuation, despite a lower profitability rank and recent insider selling activity totaling $15.0 million. Investors should weigh the undervaluation and strong fundamentals against the insider selling and market volatility.
Earnings Flash (PRVA) Privia Health Group, Inc. Reports Q2 Revenue $632.6M, Vs. FactSet Est of $597.3M
Privia Health Group, Inc. (PRVA) announced its Q2 revenue of $632.6 million, significantly surpassing the FactSet estimate of $597.3 million. This indicates stronger-than-anticipated financial performance for the quarter.
Privia Health Group Releases Q2 2026 Financial Results
Privia Health Group (PRVA) exceeded Q2 2026 earnings expectations, reporting adjusted EPS of $0.19 against a $0.07 estimate, and revenue of $632.6M, a 21.4% increase year-over-year. The company's growth was driven by its expanding provider network and value-based care arrangements, with full-year revenue guidance set at the high end of its forecast. Wall Street analysts maintain a bullish outlook on the stock.
Privia Health (NASDAQ: PRVA) lifts Q2 2026 revenue, margins and expands credit line
Privia Health Group, Inc. (NASDAQ: PRVA) reported significant financial growth for Q2 2026, with revenue increasing to $632.6 million and net income rising to $9.0 million. The company also expanded its revolving credit facility to $250 million with no outstanding borrowings, demonstrating strong liquidity. Growth was fueled by an increase in fee-for-service and value-based care, along with strategic acquisitions and an expansion into new geographical markets.
Privia Health beats Q2 estimates, issues 2026 guidance
Privia Health Group, Inc. (NASDAQ:PRVA) reported strong second-quarter results, exceeding analyst expectations with adjusted EPS of $0.19 and revenue of $632.6 million. The company also issued its first fiscal year 2026 revenue guidance, projecting between $2.35 billion and $2.45 billion, with the midpoint slightly below analyst consensus. These results highlight the company's operational execution and continued growth in its technology-driven physician enablement platform.
Privia Health Group Reports Second Quarter 2026 Results, Raises Full-Year Guidance
Privia Health Group (PRVA) announced strong second-quarter 2026 financial results, with net income rising 236.7% to $9.0 million and adjusted EBITDA increasing 29.1% to $37.4 million. Total revenue grew 21.4% to $632.6 million, leading the company to raise its full-year 2026 guidance across all key financial metrics. However, potential negatives include a significant non-cash stock compensation expense and negative cash flow from operating activities for the first half of the year.
